{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T05:07:45Z","timestamp":1788930465216,"version":"build-2803163510"},"reference-count":37,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Background\/Objectives: The prognostic nutritional index (PNI) has been associated with outcome in metastatic breast cancer, but studies in CDK4\/6 inhibitor-treated patients have used cohort-derived thresholds and examined only the pretreatment value. We assessed the PNI as a continuous variable, compared it with inflammatory indices, and examined whether repeated measurement added information. Methods: We reviewed 192 consecutive patients with hormone receptor\u2013positive, HER2-negative metastatic breast cancer treated with a CDK4\/6 inhibitor and endocrine therapy at a single centre. We calculated the PNI, neutrophil-to-lymphocyte ratio (NLR), and systemic inflammation response index (SIRI) before treatment and recalculated them before cycles 2 and 3. The Cox models were adjusted for age, liver metastasis and line of therapy; no threshold was derived from these data. Results: The median follow-up was 44.9 months. Each one-point increase in the baseline PNI was independently associated with lower hazards of progression (HR 0.952, 95% CI 0.923\u20130.983) and death (HR 0.919, 95% CI 0.884\u20130.956), corresponding to HR 0.782 (95% CI 0.670\u20130.918) and HR 0.656 (95% CI 0.540\u20130.799) per five-point increase. For overall survival, in formal comparisons on identical patient sets, neither the NLR nor the SIRI added prognostic information to a model containing the PNI (likelihood ratio p = 0.383 and p = 0.335), whereas the PNI added information to models containing either ratio (p &lt; 0.001 and p = 0.004). In exploratory landmark analyses, change in the PNI added little to the baseline value; apparent associations between increases in the NLR or SIRI by cycle 3 and overall survival did not persist after winsorisation of extreme change scores. Conclusions: Baseline PNI, analysed as a continuous variable and without a data-derived threshold, was independently associated with progression-free and overall survival in this cohort. For overall survival, neither baseline inflammatory ratio added detectable prognostic information beyond the index, and repeated measurement during treatment added little to the baseline value, although the confidence intervals do not exclude modest effects. Because all patients received a CDK4\/6 inhibitor and no comparator arm was available, these findings support a prognostic rather than a predictive interpretation, and external validation is required before the index can inform clinical decisions.<\/jats:p>","DOI":"10.3390\/jcm15176790","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T15:08:43Z","timestamp":1788275323000},"page":"6790","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Baseline and Early On-Treatment Prognostic Nutritional Index in Hormone Receptor\u2013Positive, HER2-Negative Metastatic Breast Cancer Treated with CDK4\/6 Inhibitors"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3309-7972","authenticated-orcid":false,"given":"Ezgi","family":"\u00c7oban","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Marmara University School of Medicine, Istanbul 34854, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atilla Eren","family":"Kurt","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Marmara University School of Medicine, Istanbul 34854, T\u00fcrkiye"},{"name":"Department of Internal Medicine, Istanbul Ba\u011fc\u0131lar Training and Research Hospital, Istanbul 34200, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7969-9464","authenticated-orcid":false,"given":"F\u0131rat","family":"Akag\u00fcnd\u00fcz","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Marmara University School of Medicine, Istanbul 34854, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8162-8294","authenticated-orcid":false,"given":"Ahmet","family":"Demirel","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Marmara University School of Medicine, Istanbul 34854, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1537-3032","authenticated-orcid":false,"given":"Mustafa Alperen","family":"Tun\u00e7","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Marmara University School of Medicine, Istanbul 34854, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burak","family":"Pa\u00e7ac\u0131","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Marmara University School of Medicine, Istanbul 34854, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3562-5006","authenticated-orcid":false,"given":"Ali Kaan","family":"G\u00fcren","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Marmara University School of Medicine, Istanbul 34854, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8994-2904","authenticated-orcid":false,"given":"Erkam","family":"Kocaaslan","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Marmara University School of Medicine, Istanbul 34854, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u0131nar","family":"Erel","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Marmara University School of Medicine, Istanbul 34854, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4409-6003","authenticated-orcid":false,"given":"Ye\u015fim","family":"A\u011fyol","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Marmara University School of Medicine, Istanbul 34854, T\u00fcrkiye"},{"name":"Department of Medical Oncology, Kars Harakani State Hospital, Kars 36100, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6922-1018","authenticated-orcid":false,"given":"Abdussamet","family":"\u00c7elebi","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Marmara University School of Medicine, Istanbul 34854, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2726-1740","authenticated-orcid":false,"given":"Selver","family":"I\u015f\u0131k","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Marmara University School of Medicine, Istanbul 34854, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naz\u0131m Can","family":"Demircan","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Marmara University School of Medicine, Istanbul 34854, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osman","family":"K\u00f6stek","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Marmara University School of Medicine, Istanbul 34854, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0481-1084","authenticated-orcid":false,"given":"\u0130brahim Vedat","family":"Bayo\u011flu","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Marmara University School of Medicine, Istanbul 34854, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0596-1559","authenticated-orcid":false,"given":"Murat","family":"Sar\u0131","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Marmara University School of Medicine, Istanbul 34854, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and Letrozole in Advanced Breast Cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1056\/NEJMoa2114663","article-title":"Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer","volume":"386","author":"Hortobagyi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e2100002","DOI":"10.1200\/PO.21.00002","article-title":"Systematic Review of Molecular Biomarkers Predictive of Resistance to CDK4\/6 Inhibition in Metastatic Breast Cancer","volume":"6","author":"Asghar","year":"2022","journal-title":"JCO Precis. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nature23465","article-title":"CDK4\/6 inhibition triggers anti-tumour immunity","volume":"548","author":"Goel","year":"2017","journal-title":"Nature"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1158\/2159-8290.CD-17-0915","article-title":"CDK4\/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation","volume":"8","author":"Deng","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_7","first-page":"1001","article-title":"Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients","volume":"85","author":"Onodera","year":"1984","journal-title":"Nihon Geka Gakkai Zasshi"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/jjco\/hyaf036","article-title":"Valuable predictive power of prognostic nutritional index in metastatic breast cancer patients treated with CDK4\/6 inhibitors","volume":"55","year":"2025","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2217\/fon-2022-1023","article-title":"The prognostic indicator in breast cancer treated with CDK4\/6 inhibitors: The prognostic nutritional index","volume":"19","author":"Keskinkilic","year":"2023","journal-title":"Future Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"104568","DOI":"10.1016\/j.breast.2025.104568","article-title":"Baseline neutrophil-lymphocyte ratio (NLR) predicts toxicity and survival in HR+\/HER-2 breast cancer patients treated with CDK4\/6 inhibitors","volume":"83","author":"Badran","year":"2025","journal-title":"Breast"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"21262","DOI":"10.1038\/s41598-023-47874-3","article-title":"Ratios of monocytes and neutrophils to lymphocytes in the blood predict benefit of CDK4\/6 inhibitor treatment in metastatic breast cancer","volume":"13","author":"Moukas","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"113","DOI":"10.14744\/ejmi.2025.85675","article-title":"Do inflammatory indices have prognostic value in metastatic breast cancer patients receiving CDK 4\/6 inhibitor therapy?","volume":"9","author":"Saray","year":"2025","journal-title":"EJMI"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Chen, L., Bai, P., Kong, X., Huang, S., Wang, Z., Wang, X., Fang, Y., and Wang, J. (2021). Prognostic Nutritional Index (PNI) in Patients With Breast Cancer Treated with Neoadjuvant Chemotherapy as a Useful Prognostic Indicator. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.656741"},{"key":"ref_14","first-page":"484","article-title":"Importance of prognostic nutritional index in patients with metastatic breast cancer treated with trastuzumab emtansine","volume":"6","author":"Koseci","year":"2022","journal-title":"EJMI"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Oba, T., Maeno, K., Takekoshi, D., Ono, M., Ito, T., Kanai, T., and Ito, K.I. (2020). Neoadjuvant chemotherapy-induced decrease of prognostic nutrition index predicts poor prognosis in patients with breast cancer. BMC Cancer, 20.","DOI":"10.1186\/s12885-020-6647-4"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies","volume":"370","author":"Altman","year":"2007","journal-title":"Lancet"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/jnci\/dji237","article-title":"Reporting recommendations for tumor marker prognostic studies (REMARK)","volume":"97","author":"McShane","year":"2005","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update","volume":"36","author":"Wolff","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/sim.2331","article-title":"Dichotomizing continuous predictors in multiple regression: A bad idea","volume":"25","author":"Royston","year":"2006","journal-title":"Stat. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s12957-016-0920-7","article-title":"Impact of prognostic nutritional index on long-term outcomes in patients with breast cancer","volume":"14","author":"Mohri","year":"2016","journal-title":"World J. Surg. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Hua, X., Long, Z.Q., Huang, X., Deng, J.P., He, Z.Y., Guo, L., Zhang, W.W., and Lin, H.X. (2020). The Value of Prognostic Nutritional Index (PNI) in Predicting Survival and Guiding Radiotherapy of Patients with T1-2N1 Breast Cancer. Front. Oncol., 9.","DOI":"10.3389\/fonc.2019.01562"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.12669\/pjms.39.5.7781","article-title":"Prognostic Nutritional Index (PNI) and Controlling Nutritional Status (CONUT) score for predicting outcomes of breast cancer: A systematic review and meta-analysis","volume":"39","author":"Peng","year":"2023","journal-title":"Pak. J. Med. Sci."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Qu, F., Luo, Y., Peng, Y., Yu, H., Sun, L., Liu, S., and Zeng, X. (2024). Construction and validation of a prognostic nutritional index-based nomogram for predicting pathological complete response in breast cancer: A two-center study of 1,170 patients. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1335546"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.21873\/invivo.12903","article-title":"The Modified Glasgow Prognostic Score and Prognostic Nutritional Index as Prognostic Markers in Patients with Metastatic Breast Cancer Treated with Eribulin","volume":"36","author":"Yamamoto","year":"2022","journal-title":"In Vivo"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13058-016-0794-1","article-title":"Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: A systematic review and meta-analysis","volume":"19","author":"Ethier","year":"2017","journal-title":"Breast Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1002\/cam4.2281","article-title":"Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for breast cancer patients: An updated meta-analysis of 17079 individuals","volume":"8","author":"Guo","year":"2019","journal-title":"Cancer Med."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Corbeau, I., Jacot, W., and Guiu, S. (2020). Neutrophil to Lymphocyte Ratio as Prognostic and Predictive Factor in Breast Cancer Patients: A Systematic Review. Cancers, 12.","DOI":"10.3390\/cancers12040958"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Shi, J., Liu, T., Ge, Y., Liu, C., Zhang, Q., Xie, H., Ruan, G., Lin, S., Zheng, X., and Chen, Y. (2023). Cholesterol-modified prognostic nutritional index (CPNI) as an effective tool for assessing the nutrition status and predicting survival in patients with breast cancer. BMC Med., 21.","DOI":"10.1186\/s12916-023-03225-7"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12935-020-1094-5","article-title":"Prognostic role of pretreatment blood lymphocyte count in patients with solid tumors: A systematic review and meta-analysis","volume":"20","author":"Zhao","year":"2020","journal-title":"Cancer Cell Int."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.mam.2011.12.002","article-title":"Human serum albumin: From bench to bedside","volume":"33","author":"Fanali","year":"2012","journal-title":"Mol. Asp. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"370","DOI":"10.4240\/wjgs.v7.i12.370","article-title":"Hypoalbuminemia in colorectal cancer prognosis: Nutritional marker or inflammatory surrogate?","volume":"7","author":"Nazha","year":"2015","journal-title":"World J. Gastrointest. Surg."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Ozkan, E.M., Karadag, I., Inanc, M., and Ozkan, M. (2026). Dynamic Immune-Nutritional Indices as Powerful Predictors of Pathological Complete Response in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy. J. Clin. Med., 15.","DOI":"10.3390\/jcm15020418"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Ni, J., Qi, X., Jin, C., Xu, W., Li, X., Song, L., and Zhang, X. (2025). Efficacy prediction of systemic immune-inflammation index and prognostic nutritional index in breast cancer patients and their variations after neoadjuvant chemotherapy. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1514736"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00280-024-04641-z","article-title":"Visceral obesity and sarcopenia as predictors of efficacy and hematological toxicity in patients with metastatic breast cancer treated with CDK 4\/6 inhibitors","volume":"93","author":"Aydos","year":"2024","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: An international consensus","volume":"12","author":"Fearon","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_37","first-page":"3073","article-title":"Examining guidelines and new evidence in oncology nutrition: A position paper on gaps and opportunities in multimodal approaches to improve patient care","volume":"30","author":"Prado","year":"2022","journal-title":"Support. Care Cancer"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/17\/6790\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T04:25:27Z","timestamp":1788927927000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/17\/6790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":37,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["jcm15176790"],"URL":"https:\/\/doi.org\/10.3390\/jcm15176790","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]}}}